Resialylation of sialic acid deficit vascular endothelium, circulating cells and macromolecules may counteract the development of atherosclerosis: A hypothesis

Atherosclerosis

Volumn 192, Issue 2, 2007, Pages 243-245

  Lindberg, Gunnar ^a  

^a Network for Pharmacoepidemiology Foundation   (Sweden)

Author keywords

Atherosclerosis; Hypothesis; Resialylation; Sialic acid

Indexed keywords

SIALIC ACID;

ARTICLE; ATHEROSCLEROSIS; DISEASE COURSE; HYPOTHESIS; MACROMOLECULE; PRIORITY JOURNAL; SIALYLATION; VASCULAR ENDOTHELIUM;

ATHEROSCLEROSIS; BLOOD PLATELETS; ENDOTHELIUM, VASCULAR; GLYCOLIPIDS; GLYCOPROTEINS; HUMANS; MACROPHAGES; MODELS, CARDIOVASCULAR; N-ACETYLNEURAMINIC ACID;

EID: 34248170681     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2007.03.011     Document Type: Article

References (22)

1. Lindberg G., Råstam L., Gullberg B., Lundblad A., Nilsson-Ehle P., and Hanson B.S. Serum concentrations of total sialic acid and sialoglycoproteins in relation to coronary heart disease risk markers. Atherosclerosis 103 (1993) 123-129
2. Schauer R. Chemistry, metabolism, and biological functions of sialic acids. Adv Carbohydr Chem Biochem 40 (1982) 131-234
3. Görög P., and Born G.V. Uneven distribution of sialic acids on the luminal surface of aortic endothelium. Br J Exp Pathol 64 (1983) 418-424
4. Görög P., Schraufstätter I., and Born G.V.R. Effect of removing sialic acids from endothelium on the adherence of circulating platelets on arteries in vivo. Proc R Soc Lond B Biol Sci 214 (1982) 471-480
5. Görög P., and Born G.V.R. Increase uptake of circulating LDL and fibrinogen by arterial walls after removal of sialic acids from their endothelial surface. Br J Exp Path 63 (1982) 447-451
6. Orekhov A.N., Tertov V.V., Mukhin D.N., and Mikhailenko I.A. Modification of low density lipoprotein by desialylation causes lipid accumulation in cultured cells: discover of desialylated lipoprotein with altered cellular metabolism in the blood of atheroclerotic patients. Biochem Biophys Res Commun 162 (1989) 206-211
7. Bastida E., Monteagudo J., Ordinas A., De Marco L., and Castillo R. Asialo von Willebrand factor enhances platelet adhesion to vessel subendothelium. Thromb Haemost 60 (1988) 30-34
8. Hadengue A., Razavian S.M., Del-Pino M., Simon A., and Levenson J. Influence of sialic acid on erythrocyte aggregation in hypercholesterolemia. Thromb Haemostas (Stuttgart) 76 (1996) 944-949
9. Lindberg G., Eklund G.A., Gullberg B., and Råstam L. Serum sialic acid concentration and cardiovascular mortality. BMJ 302 (1991) 143-146
10. Lindberg G., Råstam L., Gullberg B., and Eklund G.A. Serum sialic acid concentration predicts both coronary heart disease and stroke mortality: multivariate analysis including 54, 385 men and women during 20.5 years follow-up. Int J Epidemiol 21 (1992) 253-257
11. Råstam L., Lindberg G., Folsom A.R., Burke G.L., Nilsson-Ehle P., and Lundblad A. Association between serum sialic acid concentration and carotid atherosclerosis measured by B-mode ultrasound. Int J Epidemiol 22 (1996) 953-958
12. Knuiman M.W., Watts G.F., and Divitini M.L. Is sialic acid an independent risk factor for cardiovascular disease? A 17-year follow-up study in Busselton. Western Austr Ann Epidemiol 14 (2004) 627-632
13. Watts G.F., Crook M.A., Haq S., and Mandalia S. Serum sialic acid as an indicator of change in coronary artery disease. Metabolism 44 (1995) 147-148
14. Gracheva E.V., Samovilova N.N., Golovanova N.K., et al. Sialyltransferase activity of human plasma and aortic intima is enhanced in atherosclerosis. Biochim Biophys Acta 1586 (2002) 123-128
15. Resnitzky P., Yaari A., and Danon. Biophysical characteristies of erythrocytes during acute myocardial infarction and venous thrombosis. Thromb Diath Haemorrh 28 (1972) 524-532
16. Kelm S., Shukla A.K., Paulson J.C., and Schauer R. Reconstitution of the masking effect of sialic acid groups on sialidase-treated erythrocytes by the action of sialyltransferases. Carbohydr Res 149 (1986) 59-64
17. Helin-Salmivaara A., Virtanen A., Vesalainen R., et al. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur Heart J 27 (2006) 1635-1636
18. Bresalier R.S., Sandler R.S., Quan H., et al. Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352 (2005) 1092-1102
19. Solomon S.D., McMurray J.J., Pfeffer M.A., et al. Adenoma prevention with celecoxib (APC) study investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352 (2005) 1071-1080
20. Antman E.M., DeMets D., and Loscalzo J. Cyclooxygenase inhibition and cardiovascular risk. Circulation 112 (2005) 759-770
21. FitzGerald G.A., and Sherry S. Pharmacology and pharmacokinetics of platelet-active drugs under current clinical investigation. Adv Prostaglandin Thromboxane Leukot Res 10 (1982) 107-172
22. Strong J.P., Malcom G.T., McMahan C.A., et al. Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the pathobiological determinants of atherosclerosis in youth study. JAMA 281 (1999) 727-735